Skip to content Search the desk⌘ Ctrl K Agent Sign in B BridgeBio Pharma, Inc.
B BBIO BridgeBio Pharma, Inc.
B BBIO BridgeBio Pharma, Inc.
Earnings When BridgeBio Pharma, Inc. reports, what it reported each quarter, and how the stock took the results.
33 quarters. Sep 30, 2018 to Sep 30, 2026. USD.
Next results · Q4 2026 Projected
Feb 23, after the close
Tue, Feb 23, 2027 in 94 days
Projected from its last 8 releases. The company has not named the day yet.
Quarter Q4 2026 · Ends about Dec 31, 2026
10-K window Feb 19 – 26 Quarter by quarter 3 years 5 years 10 years
Revenue Net income EPS Operating income Operating cash flow Free cash flow
Q3 2026 $ 3 5 3 . 1 7 M $353.17M +192.6% vs Q3 2025
Revenue $353.17M +192.6%
Net income -$56.71M N/M
EPS -$0.42 N/M Q2 2026 Aug 10, 2026, after the closeBridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Revenue $243.68M +120.4%
Net income -$155.89M N/M
EPS -$0.78 N/M
Revenue $194.52M +66.8%
Net income -$166.56M N/M
EPS -$0.84 N/M
Revenue $154.18M +2,521.2%
Net income -$188.82M N/M
EPS — —
Results day Typical move ±5.1% A typical move of 5.1% either way
Up after 4 of 12, down after 8.
−6.3% −8.8% +0.9%
When it reports
Usual day Varies
After quarter end 29 to 51 days
10-Q filed 29 to 41 days over its last 8
10-K filed 53 to 56 days over its last 7 ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d ended Dec 31, 2024 · filed Feb 20, 2025 · 51 d ended Mar 31, 2025 · filed Apr 29, 2025 · 29 d ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d ended Sep 30, 2025 · filed Oct 29, 2025 · 29 d ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d FY 2026 Q3 2026 Sep 30, 2026 Oct 29, 2026 · after-hours Oct 29, 2026 29 d 10-Q $353.17M +192.6% -$0.42 +6.0% Q2 2026 Jun 30, 2026 Aug 10, 2026 · after-hours Aug 10, 2026 41 d 10-Q $243.68M +120.4% -$0.78 1.1% Q1 2026 Mar 31, 2026 May 7, 2026 · after-hours May 7, 2026 37 d 10-Q $194.52M +66.8% -$0.84 0.1%
FY 2025 Q4 2025 derived Dec 31, 2025 Feb 24, 2026 · after-hours Feb 24, 2026 55 d 10-K $154.18M +2,521.2% — 2.7% Q3 2025 Sep 30, 2025 Oct 29, 2025 · after-hours Oct 29, 2025 29 d 10-Q $120.70M +4,318.0% -$0.95 4.8% Q2 2025 Jun 30, 2025 Aug 5, 2025 · after-hours Aug 5, 2025 36 d 10-Q $110.57M +4,999.9% -$0.95 8.9% Q1 2025 Mar 31, 2025 Apr 29, 2025 · after-hours Apr 29, 2025 29 d 10-Q $116.63M −44.8% -$0.88 +5.4%
FY 2024 Q4 2024 derived Dec 31, 2024 Feb 20, 2025 · pre-market Feb 20, 2025 51 d 10-K $5.88M +237.1% — +1.3% Q3 2024 Sep 30, 2024 Nov 12, 2024 · pre-market Nov 12, 2024 43 d 10-Q $2.73M −33.2% -$0.86 5.7% Q2 2024 Jun 30, 2024 Aug 1, 2024 · pre-market Aug 1, 2024 32 d 10-Q $2.17M +32.1% -$0.39 +0.9% Q1 2024 Mar 31, 2024 May 2, 2024 · pre-market May 2, 2024 32 d 10-Q $211.12M +11,461.9% -$0.20 —
FY 2023 Q4 2023 derived Dec 31, 2023 Feb 22, 2024 · pre-market Feb 22, 2024 53 d 10-K $1.75M −6.7% — — Q3 2023 Sep 30, 2023 Nov 2, 2023 · pre-market Nov 2, 2023 33 d 10-Q $4.09M +1,110.4% -$1.08 — Q2 2023 Jun 30, 2023 Aug 3, 2023 · pre-market Aug 3, 2023 34 d 10-Q $1.64M −97.8% -$0.98 8.8% Q1 2023 Mar 31, 2023 May 4, 2023 · pre-market May 4, 2023 34 d 10-Q $1.83M +7.8% -$0.92 6.3%
FY 2022 Q4 2022 derived Dec 31, 2022 Feb 23, 2023 · pre-market Feb 23, 2023 54 d 10-K $1.87M −85.5% — 4.7% Q3 2022 Sep 30, 2022 Nov 3, 2022 · after-hours Nov 3, 2022 34 d 10-Q $338.00K −85.6% -$0.93 5.7% Q2 2022 Jun 30, 2022 Aug 4, 2022 · after-hours Aug 4, 2022 35 d 10-Q $73.75M +36.5% -$0.07 +32.3% Q1 2022 Mar 31, 2022 — May 5, 2022 35 d 10-Q $1.69M +266.7% -$1.35 32.1%
FY 2021 Q4 2021 derived Dec 31, 2021 Feb 24, 2022 · pre-market Feb 25, 2022 56 d 10-K $12.89M — — +7.6% Q3 2021 Sep 30, 2021 Nov 4, 2021 · pre-market Nov 4, 2021 35 d 10-Q $2.34M −71.2% -$1.06 +2.9% Q2 2021 Jun 30, 2021 — Aug 5, 2021 36 d 10-Q $54.02M — -$0.66 6.9% Q1 2021 Mar 31, 2021 — May 6, 2021 36 d 10-Q $462.00K — -$1.18 3.1%
FY 2020 Q4 2020 derived Dec 31, 2020 — Feb 25, 2021 56 d 10-K — — — +8.5% Q3 2020 Sep 30, 2020 Nov 5, 2020 · pre-market Nov 5, 2020 36 d 10-Q $8.13M −69.6% -$0.98 +2.8% Q2 2020 Jun 30, 2020 Aug 11, 2020 · pre-market Aug 11, 2020 42 d 10-Q — — -$1.03 — Q1 2020 Mar 31, 2020 May 13, 2020 · after-hours May 14, 2020 44 d 10-Q — — -$0.78 +13.1%
FY 2019 Q4 2019 derived Dec 31, 2019 Mar 2, 2020 · pre-market Mar 3, 2020 63 d 10-K — — — 9.3% Q3 2019 Sep 30, 2019 — Nov 8, 2019 39 d 10-Q $26.74M — -$0.51 +26.2% Q2 2019 Jun 30, 2019 — Aug 14, 2019 45 d 10-Q — — -$0.71 0.0% Q1 2019 Mar 31, 2019 — — — — — — -$0.66 —
FY 2018 Q4 2018 derived Dec 31, 2018 — — — — — — — — Q3 2018 Sep 30, 2018 — — — — — — -$0.52 —
Earlier years, FY 2018 to FY 2023 The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
10-Q
May 7, 2026
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
Year over year, last four quarters
Revenue $154.18M Revenue, change from a year earlier: Q3 2026 +192.6%, Q2 2026 +120.4%, Q1 2026 +66.8%, Q4 2025 +2,521.2% +2,521.2% +66.8% +120.4% +192.6%
Net income -$188.82M Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m n/m n/m n/m n/m
EPS — EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m n/m n/m n/m n/m +6.0% by the close of Oct 30
Thaler Research Engraved from SEC EDGAR © 2026 Thaler. All rights reserved. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
1.1% by the close of Aug 11
ended Mar 31, 2026 · filed May 7, 2026 · 37 d ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d ended Sep 30, 2026 · filed Oct 29, 2026 · 29 d window Feb 19 – 26 · projected The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −8.9% after Q2 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Provenance Data status and checks